Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...

Clinical Trials

Open Label Extension Study of INBRX-101 in Adults With AATD Emphysema

Phase 2

Recruiting

Conditions: Alpha 1-Antitrypsin Deficiency
Emphysema

Interventions: Drug: INBRX-101

First Posted Date: 2023-06-09

Last Posted Date: 2024-07-03

Lead Sponsor: Sanofi

Target Recruit Count: 130

Registration Number: NCT05897424

Locations: 🇦🇺
Lung Research Qld, Chermside, Queensland, Australia

Dupilumab in Chinese Adult Participants With CRSwNP

Phase 3

Completed

Conditions: Chronic Rhinosinusitis With Nasal Polyps

Interventions: Drug: Placebo
Drug: Dupilumab
Drug: Budesonide

First Posted Date: 2023-05-26

Last Posted Date: 2024-12-17

Lead Sponsor: Sanofi

Target Recruit Count: 63

Registration Number: NCT05878093

Locations: 🇨🇳
Investigational Site Number : 1560016, Jinan, China
🇨🇳
Investigational Site Number : 1560001, Beijing, China
🇨🇳
Investigational Site Number : 1560010, Chengdu, China

and more 15 locations

Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: SAR444336

First Posted Date: 2023-05-25

Last Posted Date: 2023-12-22

Lead Sponsor: Sanofi

Target Recruit Count: 76

Registration Number: NCT05876767

Locations: 🇳🇱
Investigational Site Number :5280002, Groningen, Netherlands
🇳🇱
Investigational Site Number :5280001, Leiden, Netherlands

A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: SAR441566

First Posted Date: 2023-05-15

Last Posted Date: 2023-08-21

Lead Sponsor: Sanofi

Target Recruit Count: 10

Registration Number: NCT05858788

Locations: 🇺🇸
Parexel International-Site Number:8400001, Glendale, California, United States

Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

Phase 2

Recruiting

Conditions: Alpha 1-Antitrypsin Deficiency
Emphysema

Interventions: Drug: INBRX-101
Drug: Zemaira

First Posted Date: 2023-05-12

Last Posted Date: 2024-07-03

Lead Sponsor: Sanofi

Target Recruit Count: 90

Registration Number: NCT05856331

Locations: 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
University of Miami, Miami, Florida, United States

and more 36 locations

A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

Phase 2

Active, not recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: SAR442970
Drug: Placebo

First Posted Date: 2023-05-09

Last Posted Date: 2024-09-30

Lead Sponsor: Sanofi

Target Recruit Count: 86

Registration Number: NCT05849922

Locations: 🇺🇸
Center for Clinical Studies, LTD. LLP Site Number : 8400003, Houston, Texas, United States
🇦🇺
Investigational Site Number : 0360002, Liverpool, New South Wales, Australia
🇫🇷
Investigational Site Number : 2500004, Saint Mande, France

and more 47 locations

A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects

Phase 1

Completed

Conditions: Osteochondrodysplasia

Interventions: Drug: Placebo
Drug: SAR442501

First Posted Date: 2023-05-06

Last Posted Date: 2024-08-27

Lead Sponsor: Sanofi

Target Recruit Count: 76

Registration Number: NCT05846009

Locations: 🇺🇸
Investigational site, Newark, New Jersey, United States

Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: SAR441344
Drug: placebo
Biological: Keyhole limpet hemocyanin

First Posted Date: 2023-05-06

Last Posted Date: 2023-09-28

Lead Sponsor: Sanofi

Target Recruit Count: 56

Registration Number: NCT05845996

Locations: 🇺🇸
PPD-Site Number:8400001, Austin, Texas, United States

A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: SAR441566
Drug: Ciprofloxacin

First Posted Date: 2023-05-06

Last Posted Date: 2024-01-18

Lead Sponsor: Sanofi

Target Recruit Count: 60

Registration Number: NCT05844735

Locations: 🇺🇸
TKL Research, Inc. Site Number : 8400001, Fair Lawn, New Jersey, United States

A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Phase 1

Recruiting

Conditions: Relapsed/Refractory Multiple Myeloma
Amyloid Light-chain Amyloidosis

Interventions: Drug: SAR445514

First Posted Date: 2023-05-03

Last Posted Date: 2024-11-04

Lead Sponsor: Sanofi

Target Recruit Count: 111

Registration Number: NCT05839626

Locations: 🇦🇺
Investigational Site Number : 0360001, Wollongong, New South Wales, Australia
🇦🇺
Investigational Site Number : 0360002, Richmond, Victoria, Australia
🇧🇪
Institut Jules Bordet_Site Number : 0560002, Anderlecht, Belgium

and more 13 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy